CMIC: Comprehensive Bioanalytical Services to Optimize Drug Development

The pharmaceutical and biotech arena is mainly driven by enormous potential to treat a wide array of human diseases using a diverse class of therapeutic products. In this era of ever changing technologies and therapeutic approaches, bio-analytical laboratories or CROs need to diligently reassess new technologies and operational methodology to support rapid characterization and quantification needs. With more than 30 years of bioanalysis experience in supporting wide range of drug development programs, CMIC, Inc. has accumulated enormous “know-how” and consistently demonstrated its scientific expertise in the field. “Innovation is part of our corporate DNA. We are investing ahead of the curve in new technologies— becoming a strong arm to our clients resolving their most challenging bioanalysis issues,” says Mike Suga, President, and CEO of CMIC. “We directly participate in bioanalysis global harmonization, seamlessly supporting drug development efforts across continents with rapid and smooth tech transfer.”

Bioanalysis is used very early on in the drug development process to provide support to drug discovery programs. It also plays a critical role throughout the preclinical and clinical drug development phases for decision-making and into post-marketing support. “The bio¬analytical market is becoming competitive and fragmented. In order to thrive in this market, the CRO must proffer high quality data and deliver it at reasonable cost,” adds Suga. “The continued need to provide quality, flexible, and secure data is fast posing as a challenge.” Upon acquiring their Chicago lab last year, CMIC invested in the latest generation of computer servers, data storage and security software to further ensure the security of their data.The company brought on additional modules on their LIMS (Laboratory Information Management System) and learned the processes around the lab to further enhance their data quality. These improvements along with joining the larger CMIC group continue to support CMIC’s strategic program management offerings such as Toxicokinetics, Pharmacokinetic, Pharmacodynamic, and clinical value chain.